Twenty one subjects with AD and eighteen age-matched control subjects participated in this study after giving written, informed consent. For those AD patients who were unable to give informed consent, written, informed consent was obtained from their legal guardian. The study protocol was approved by the Stanford University Institutional Review Board. The AD subjects (10 males, 11 females) ranged in age from 48 to 83 (mean age 63.97) with 12 to 22 years of education (mean years of education 15.89). The subjects were recruited from memory disorder clinics in Stanford University and the University of California San Francisco (UCSF). All AD subjects met the NINDS-ADRDA criteria for probable AD [43]. One subject had a presenilin-1 mutation; a second subject's mother had a presenilin-2 mutation (the subject herself did not wish to be tested). Diagnosis of three other subjects has since been confirmed at autopsy. ApoE status was known for 4 additional AD subjects: one was homozygous for the ApoE 4 allele and 3 were heterozygous for the ApoE 4 allele. The control subjects (10 males, 8 females) ranged in age
